Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMETHOD Health. In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may…READ MORE
The Latest
Fox News: AI tool gives doctors personalized Alzheimer’s treatment plans for dementia patients
May 8, 2023
More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE
Quest Diagnostics and uMETHOD Health, Inc. are excited to announce the national launch of a robust solution in the fight against dementia. Using a 3-step approach that combines our advanced testing with uMETHOD’s AI-based technology, you can help patients prevent cognitive decline, improve brain health, and maintain independence. Learn more about Quest Diagnostic's Alzheimer's disease testing portfolio at Questforthecure.com or contact a uMETHOD Health representative today.…READ MORE
Studies Show Links Between Chronic Kidney Disease and Memory Loss, What Can You Do About It?
March 27, 2023
World Kidney Day has been observed in early March since 2006; in the US, March is National Kidney Month. Efforts to increase awareness of kidney health are timely, as chronic kidney disease (CKD) affected an estimated 37 million Americans in 2021. Drugs prescribed for common illnesses can increase the risk or severity of CKD. This risk comes in addition to drug-to-drug interactions (DDIs) that might also exacerbate CKD. And unfortunately,…READ MORE
Today’s standard of care for complex diseases like Alzheimer’s Disease (AD) and related dementias fails to meet the needs of an aging patient population. It falls short of providing adequate guidance for clinicians who bear the burden of this care gap. Complex diseases proceed from many contributing factors -- medical, genetic, and environmental -- that vary widely from person to person. Untangling the web of factors that contribute to neurodegeneration can…READ MORE
Despite our annual expressions of gratitude to our veterans for all they’ve sacrificed, we fall short when it comes to their health and well-being. In addition to cancer, diabetes, and mental-health disorders, veterans suffer from Alzheimer’s Disease (AD) and other forms of dementia at high rates. Veterans currently under a physician’s care need a comprehensive workup and a care plan that addresses the factors that drive the progression of AD.…READ MORE
PathGroup and uMETHOD Health Partner to Personalize Care for Mild Cognitive Impairment (MCI) and Early-stage Alzheimer’s Disease Patients
November 10, 2022
NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD's AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient's risk of developing Alzheimer's and disease progression in its early stages. Read the full release.…READ MORE
What’s the connection between Alzheimer’s Disease (AD) and falls among senior adults?
September 21, 2022
uMETHOD Health is partnering with regional and national diagnostic laboratories and hundreds of physicians to identify and address the multiple factors that contribute to cognitive issues in seniors. The Raleigh, NC-based company produces leading-edge medical artificial intelligence (AI) and services to target complex diseases such as Alzheimer’s Disease (AD). On the 29th annual World Alzheimer’s Day, uMETHOD states there are multiple contributors involved in the progression of AD and they…READ MORE
uMETHOD, Getlabs partner to make personalized cognitive decline care plans accessible in Arizona
September 9, 2022
uMETHOD, which provides precision medicine software to treat cognitive decline, tapped at-home diagnostics provider Getlabs to supply mobile phlebotomies for its patients in Arizona. Blood tests are an essential part of the personalized care plans that uMETHOD provides, and the partnership seeks to make these tests accessible to patients with cognitive decline. Read the full article here.…READ MORE
uMETHOD’s AI software helps doctors assess and reduce risk of falls among patients with cognitive decline
July 22, 2022
uMETHOD Health is a technology company in Research Triangle Park, North Carolina, focused on treating the causes of complex diseases. Its RestoreU METHOD uses patented artificial-intelligence (AI) software to identify the underlying factors that drive someone’s cognitive decline. This software generates personalized care plans on how to prevent, slow, or even roll-back the progression of cognitive decline. The software now identifies all the drugs someone may be taking that increase…READ MORE